Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Audit MicroControls’ MicroFD urine chemistry control, two levels, is intended to simulate human patient samples for monitoring the precision of laboratory testing procedures for urine chemistry assays, including amylase, calcium, chloride, creatinine, glucose, magnesium, microalbumin, microprotein, phosphorous, potassium, sodium, urea nitrogen, and uric acid.
Quest Diagnostics offers a clinical test panel for aiding the diagnosis of suspected dementia due to treatable forms of cognitive impairment. The panel is believed to be the first commercial service from a clinical laboratory to combine several guideline-recommended tests for identifying secondary, treatable causes of dementia as a single blood test and report.
Randox Laboratories’ www.riqas.com allows users to discover the benefits offered by the Randox International Quality Assessment Scheme (RIQAS) and the advantages of implementing external quality assessment (EQA). The Web site displays information on well-designed, easy-to-navigate pages.
Bio/Data Corp.’s Collagen synthetic reactive peptide (SRP) is a synthetic type-1 collagen-like liquid polypeptide that self-assembles into a helix to form fibrils. Synthetic collagen may be useful in laboratories investigating platelet function and reactivity, platelet activation, and cellular analysis.
Qiagen offers a sample-to-result next-gen sequencing workflow designed to enable the routine use of NGS technology in areas such as clinical research and diagnostics. Qiagen’s NGS workflow is an ecosystem of products and services that offer automated processes from primary sample to digital result.
Eppendorf North America’s µCuvette G1.0 is for measuring small volumes of highly concentrated biomolecules, such as proteins and nucleic acids. Users can work easily with samples as small as 1.5 μL, without the need for a time-consuming dilution step. The μCuvette G1.0 expands the measuring range of the Eppendorf BioPhotometer and BioSpectrometer.
Roche has received FDA approval for its Cobas AmpliPrep/Cobas TaqMan HCV test, v2.0. The next-generation viral load test is for use in the management of patients with chronic hepatitis C virus infection. The test provides a novel dual-probe approach, for an extra layer of protection in detecting and quantifying the virus and is designed to accurately determine the amount of HCV RNA to assess a patient’s response to antiviral therapy.
Agilent Technologies’ SureSelect strand-specific RNA library preparation kit for whole transcriptome and targeted RNA sequencing allows researchers to prepare high-quality, strand-specific libraries for next-generation sequencing. The ability to gain strand-specific information from RNA sequencing experiments allows researchers to more easily discern overlapping transcripts and investigate antisense expression to better understand gene regulation.
Cerilliant offers certified spiking solutions for use in preparing T4-13C6, T3-13C6, and reverse T3-13C6 calibrators and controls for monitoring free and total thyroid hormone levels in serum or plasma by liquid chromatography-tandem mass spectrometry. These products offer clinical and endocrinology labs the full range of stable-labeled internal standards necessary for accurate quantitation of T4, T3, and reverse T3, using LC-MS/MS.
Vector Laboratories now offers its ImmPress polymer detection reagents with alkaline phosphatase as the enzyme detection system. Available as anti-mouse and anti-rabbit ImmPress-AP alkaline-phosphatase polymer reagents, these products are designed to detect primary antibodies made in rabbit and mouse in immunohistochemical staining. They provide greater sensitivity than conventional alkaline-phosphatase antibody conjugates and other alkaline-phosphatase detection reagents.
